A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 76 (planned)
- Started
- Sep 19, 2025
- Main results expected
- Feb 5, 2027
- Fully finished
- Oct 25, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Maximum observed serum concentration (Cmax) of subcutaneous Nivolumab in serum
Measured over: Up to 3 weeks
Time to peak concentration (Tmax) of subcutaneous Nivolumab in serum
Measured over: Up to 3 weeks
Area under the concentration-time curve within a dosing interval (AUC(TAU)) of subcutaneous Nivolumab in serum
Measured over: Up to 3 weeks
Concentration at the end of a dosing interval (Ctau) of subcutaneous Nivolumab in serum
Measured over: Up to 3 weeks
Trough observed concentration (Ctrough) of subcutaneous Nivolumab
Measured over: At Cycle 7 Day 1 (Week 18)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06946797 · record last updated 2026-05-14 · checked 2026-11-09 15:47 UTC